Janel Long-Boyle, PharmD, PhD

Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.
Honors and Awards
  • UCSF Gary Rifkind Research Award for Junior Faculty, UCSF School of Pharmacy, 2012
  • Early Career Award, Thrasher Research Fund, 2010-2012
Websites

  1. Mike JK, White Y, Ha J, Iranmahboub A, Hawkins C, Hutchings RS, Vento C, Manzoor H, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E. Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia. Stroke 2024. PMID: 39429154


  2. Bognàr T, Garcia-Rosa M, Lalmohamed A, Güngör T, Hauri-Hohl MM, Prockop SE, Oram LM, Pai SY, Brooks J, Savic RM, Dvorak CC, Long-Boyle JR, Krajinovic M, Bittencourt H, Teyssier AC, Theoret Y, Martinez C, Egberts TCG, Morales E, Slatter MA, Cuvelier GDE, Chiesa R, Wynn R, Coussons M, Cicalese MP, Ansari M, Long SE, Ebens CL, Lust H, Chaudhury S, Nath CE, Shaw PJ, Keogh SJ, van der Stoep E, Bredius RG, Lindemans CA, Boelens JJ, Bartelink IH. Association of Busulfan Exposure and Outcomes after HCT for Patients with an Inborn Error of Immunity. Blood advances 2024. PMID: 39074263


  3. Dvorak CC, Long-Boyle JR, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, Talano JA, Bunin NJ, Anderson EJ, Flower A, Lalefar NR, Higham CS, Kapoor N, Klein O, Odinakachukwu MC, Cho S, Jacobsohn DA, Collier W, Pulsipher MA. Effect of Rabbit ATG PK on Outcomes after TCR-αβ/CD19-depleted Pediatric Haploidentical HCT for Hematologic Malignancy. Blood advances 2024. PMID: 39042892


  4. Jung D, Long-Boyle JR, Pang WW, Gobburu JVS. Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients with Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Transplantation and cellular therapy 2024. PMID: 38972509


  5. Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, Dara J, Huang JN, Hermiston ML, Long-Boyle JR, Dvorak CC. Cyclophosphamide and thiotepa increases risk of transplant-associated thrombotic microangiopathy. Transplantation and cellular therapy 2024. PMID: 38944154


  6. Cisneros GS, Dvorak CC, Long-Boyle J, Kharbanda S, Shimano KA, Melton A, Chu J, Winestone LE, Dara J, Huang JN, Hermiston ML, Zinter M, Higham CS. Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols. Transplantation and cellular therapy 2024. PMID: 38631464


  7. Hughes JH, Long-Boyle J, Keizer RJ. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. Journal of pharmacokinetics and pharmacodynamics 2024. PMID: 38520573


  8. Mike JK, White Y, Hutchings RS, Vento C, Ha J, Iranmahboub A, Manzoor H, Gunewardena A, Cheah C, Wang A, Goudy BD, Lakshminrusimha S, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E. Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Children (Basel, Switzerland) 2023. PMID: 38002819


  9. Long-Boyle JR, Kohn DB, Shah AJ, Spencer SM, Sevilla J, Booth C, López Lorenzo JL, Nicoletti E, Shah A, Reatz M, Matos J, Schwartz JD. Busulfan and subsequent malignancy: An evidence-based risk assessment. Pediatric blood & cancer 2023. PMID: 37856098


  10. Mike JK, White Y, Hutchings RS, Vento C, Ha J, Manzoor H, Lee D, Losser C, Arellano K, Vanhatalo O, Seifert E, Gunewardena A, Wen B, Wang L, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Wu YW, Fineman JR, Ferriero DM, Maltepe E. Perinatal Azithromycin Provides Limited Neuroprotection in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Stroke 2023. PMID: 37846563


  11. Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, Dara J, Long-Boyle J, Oh J, Chan W, Chag S, Broderick L, Chellapandian D, Decaluwe H, Golski C, Hu D, Kuo CY, Miller HK, Petrovic A, Currier R, Hilton JF, Punwani D, Dvorak CC, Malech HL, McIvor RS, Puck JM. Lentiviral Gene Therapy for Artemis-Deficient SCID. The New England journal of medicine 2022. PMID: 36546626


  12. Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, Long S, Gupta AO, Horn B, Lamba JK, Huang L, Apsel-Winger B, Keizer RJ, Savic R, Long-Boyle J. Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation. Pharmaceutics 2022. PMID: 36432661


  13. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. Journal of chromatography open 2022. PMID: 35875822


  14. Mike JK, Wu KY, White Y, Pathipati P, Ndjamen B, Hutchings RS, Losser C, Vento C, Arellano K, Vanhatalo O, Ostrin S, Windsor C, Ha J, Alhassen Z, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JV, Long-Boyle J, Chen P, Wu YW, Fineman JR, Ferriero DM, Maltepe E. Defining longer term outcomes in an ovine model of moderate perinatal hypoxia-ischemia. 2022. PMID: 35588703


  15. Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Winger BA. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. 2022. PMID: 35048362


  16. Bognàr TT, Bartelink IIH, Egberts TACG, Rademaker CCMA, Versluys BAB, Slatter MMA, Kletzel MM, Nath CCE, Cuvelier GGDE, Savic RRM, Dvorak CC, Long-Boyle JJR, Cowan MMJ, Bittencourt HH, Bredius RRGM, Güngör TT, Shaw PPJ, Ansari MM, Hassan MM, Krajinovic MM, Hempel GG, Marktel SS, Chiesa RR, Théoret YY, Lund TT, Orchard PPJ, Wynn RRF, Boelens JJJJ, Lalmohamed AA. Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation. 2022. PMID: 35065280


  17. Brooks JT, Keizer RJ, Long-Boyle JR, Kharbanda S, Dvorak CC, Friend BD. Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation. 2021. PMID: 34950026


  18. Takahashi T, Illamola SM, Jennissen CA, Long SE, Lund TC, Orchard PJ, Gupta AO, Long-Boyle JR. Busulfan dose recommendation in inherited metabolic disorders: Population pharmacokinetic analysis. 2021. PMID: 34883294


  19. Bankova AK, Pang W, Velasco BJ, Long-Boyle JR, Shizuru JA. 5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood advances 2021. PMID: 34448832


  20. Apsel Winger B, Long SE, Brooks J, Gupta AO, Dvorak CC, Long-Boyle JR. A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults. Frontiers in pediatrics 2021. PMID: 34350148


  21. Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood advances 2021. PMID: 33877298


  22. Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, Dvorak CC, Long-Boyle J. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transplantation and cellular therapy 2020. PMID: 33781528


  23. Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL, IGNITE Pharmacogenetics Working Group. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA network open 2020. PMID: 33315113


  24. Shukla P, Dvorak CC, Long-Boyle J, Kharbanda S. Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients. International journal of molecular sciences 2020. PMID: 32781600


  25. Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Frontiers in pharmacology 2020. PMID: 32714184


  26. Contreras CF, Long-Boyle JR, Shimano KA, Melton A, Kharbanda S, Dara J, Higham C, Huang JN, Cowan MJ, Dvorak CC. Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020. PMID: 32534101


  27. Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. Journal of clinical pharmacology 2020. PMID: 32476174


  28. Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget 2020. PMID: 32523649


  29. Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. The New England journal of medicine 2019. PMID: 30995372


  30. Wang H, Jones AK, Dvorak CC, Huang L, Orchard P, Ivaturi V, Long-Boyle J. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019. PMID: 31002993


  31. Dvorak CC, Long-Boyle J, Dara J, Melton A, Shimano KA, Huang JN, Puck JM, Dorsey MJ, Facchino J, Chang CK, Cowan MJ. Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019. PMID: 30876930


  32. Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J. Determination of melphalan in human plasma by UPLC-UV method. Cancer chemotherapy and pharmacology 2019. PMID: 30847504


  33. Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, Krtolica A, Maltepe E. Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS biology 2019. PMID: 30677022


  34. Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B. A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service. Journal of the American College of Clinical Pharmacy : JACCP 2018. PMID: 32391517


  35. Boehme J, Le Moan N, Kameny RJ, Loucks A, Johengen MJ, Lesneski AL, Gong W, Goudy BD, Davis T, Tanaka K, Davis A, He Y, Long-Boyle J, Ivaturi V, Gobburu JVS, Winger JA, Cary SP, Datar SA, Fineman JR, Krtolica A, Maltepe E. Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS biology 2018. PMID: 30335746


  36. Czechowicz JA, Long-Boyle JR, Rosbe KW, Mathes EF, Frieden IJ, Shimano KA. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants. International journal of pediatric otorhinolaryngology 2017. PMID: 29447818


  37. Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long-Boyle J, Hedlin H, Zamanian RT. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. The European respiratory journal 2017. PMID: 28893866


  38. Cowan MJ, Dvorak CC, Long-Boyle J. Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy. Hematology/oncology clinics of North America 2017. PMID: 28895849


  39. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017. PMID: 28684371


  40. Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget 2017. PMID: 27793021


  41. Bartelink IH, Lalmohamed A, Long-Boyle JR, Boelens JJ. Busulfan after HSCT in children and young adults - Authors' reply. The Lancet. Haematology 2017. PMID: 28257750


  42. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. The Lancet. Haematology 2016. PMID: 27746112


  43. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clinical pharmacokinetics 2016. PMID: 26620047


  44. Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Translational research : the journal of laboratory and clinical medicine 2016. PMID: 27094990


  45. Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. American journal of respiratory and critical care medicine 2015. PMID: 26177174


  46. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Therapeutic drug monitoring 2015. PMID: 25162216


  47. Miyagi SJ, Long-Boyle JR. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics. Drug metabolism letters 2015. PMID: 26031462


  48. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2014. PMID: 24820973


  49. French D, Sujishi KK, Long-Boyle JR, Ritchie JC. Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan. Therapeutic drug monitoring 2014. PMID: 24625541


  50. Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC, workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. The Journal of allergy and clinical immunology 2013. PMID: 24139498


  51. Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013. PMID: 24029650


  52. Huang L, Lizak P, Aweeka F, Long-Boyle J. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. Journal of pharmaceutical and biomedical analysis 2013. PMID: 24013121


  53. Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. British journal of clinical pharmacology 2013. PMID: 22765258


  54. Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012. PMID: 22609040


  55. Kim H, Long-Boyle J, Rydholm N, Orchard PJ, Tolar J, Smith AR, Jacobson P, Brundage R. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. Journal of clinical pharmacology 2011. PMID: 22110162


  56. Long-Boyle J, Huang J, Rydholm N, Smith A, Orchard P, Tolar J, Jacobson P. Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. Journal of clinical pharmacology 2010. PMID: 20525919


  57. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone marrow transplantation 2010. PMID: 20383215


  58. Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, DeFor T, Jennissen C, Brunstein C, Wagner J, Tomblyn M, Weisdorf D. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone marrow transplantation 2009. PMID: 19151792


  59. Jacobson P, Long J, Rogosheske J, Brunstein C, Weisdorf D. High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005. PMID: 16338619


  60. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, Tan Y, Long J, Remmel R, Sawchuk R, McGlave P. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clinical pharmacology and therapeutics 2005. PMID: 16321615


  61. Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, Lentz SR. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003. PMID: 12609838